GLP-1 receptor agonists like semaglutide may contribute to night sweats through overlapping thermoregulatory pathways: autonomic effects that can sustain sympathetic activity, brown adipose tissue thermogenesis through hypothalamic GLP-1 pathways, and changes in the core body temperature drop that supports sleep onset. FDA pharmacovigilance data identifies hyperhidrosis as a statistically significant cutaneous adverse-event signal for the drug class (Daniel et al., 2025).
Night sweats are commonly reported in GLP-1 drug user communities, although controlled trials usually group sweating reports together rather than separating nocturnal sweating from daytime sweating. FDA adverse-event data identifies hyperhidrosis as one of the five most common reported cutaneous adverse reactions across six GLP-1 agonists, with a statistically significant reporting difference by indication (reported as P = 0.000; Daniel et al., 2025). Published work has not yet separated semaglutide-specific nocturnal sweating from broader GLP-1 sweating, thermoregulation, and autonomic data.
This article covers three physiological pathways through which semaglutide may affect nocturnal thermoregulation: autonomic activation, brown adipose tissue thermogenesis, and core body temperature dynamics. It also addresses the adaptation timeline and when night sweats tend to resolve. For the full overview of all GLP-1 sleep effects, see the parent article: Does Ozempic Cause Insomnia What GLP-1 Drugs Do to Your Sleep.
GLP-1 drugs can disrupt sleep through several distinct pathways. This article covers the thermoregulatory mechanism. Other articles in this series cover orexin-driven wakefulness, blood sugar crashes, vivid dreams, and circadian disruption.
Why Does Ozempic Cause Night Sweats
Central GLP-1 can influence temperature regulation: in 1996, central GLP-1 injection produced a measurable core body temperature reduction over two hours, and the effect was blocked by the GLP-1 receptor antagonist exendin 9-39 (O’Shea et al., 1996). Semaglutide and related GLP-1 receptor agonists can engage central and peripheral GLP-1 pathways, although the degree of semaglutide CNS penetration is still being clarified. At the same time, GLP-1 receptor agonism can increase sympathetic markers and stimulate brown adipose tissue to produce heat. The likely result is a thermoregulatory state where heat production, autonomic tone, and sweating thresholds may no longer align cleanly during sleep.
How Does Central Glucagon-Like Peptide-1 Regulate Body Temperature
The connection between GLP-1 and body temperature was established before semaglutide existed. In 1996, intracerebroventricular injection of GLP-1 produced a reduction in core body temperature over two hours in animal models. Both the temperature effect and food intake reduction were blocked by the GLP-1 receptor antagonist exendin 9-39, establishing that these effects are receptor-mediated. Peripheral injection also reduced temperature but did not affect food intake — demonstrating that central and peripheral GLP-1 pathways diverge in their downstream targets (O’Shea et al., 1996).
This matters because semaglutide acts on the GLP-1 receptor, including GLP-1 pathways relevant to appetite, autonomic regulation, and temperature biology. The anatomical separation of temperature and appetite pathways in GLP-1 biology suggests thermoregulatory effects may not track perfectly with satiety and weight-loss effects.
Does Ozempic Increase Heat Production Through Brown Adipose Tissue
GLP-1 agonists also increase heat production through brown adipose tissue (BAT). The pathway runs through inhibition of AMP-activated protein kinase (AMPK) in the ventromedial nucleus of the hypothalamus. When hypothalamic AMPK is inhibited, sympathetic drive to brown adipose tissue increases, activating uncoupling protein 1 (UCP-1) — the molecular mediator of heat generation in BAT. A one-year longitudinal study of individuals with obesity and type 2 diabetes showed that both exenatide and liraglutide increased energy expenditure in humans, providing translational validation of the preclinical thermogenesis data (Beiroa et al., 2014).
Image: DMH GLP-1R stimulation increases BAT thermogenesis.
Why Is the Dorsomedial Hypothalamus the Key Thermoregulatory Hub
The dorsomedial hypothalamus (DMH) is one site where GLP-1 receptor activity can influence sympathetic outflow to brown adipose tissue. Direct GLP-1 injection into the DMH enhanced BAT thermogenesis, while viral knockdown of DMH GLP-1 receptors reduced BAT temperature and UCP-1 expression. Lee et al. found DMH GLP-1 receptors on GABAergic neurons involved in BAT regulation; sweat glands are separately activated by sympathetic cholinergic fibers (Lee et al., 2018; Kenny, 2018).
This is the anatomical bridge: hypothalamic GLP-1 signaling can increase BAT thermogenesis, while eccrine sweat glands respond to sympathetic cholinergic activation. The sweating link is therefore mechanistically plausible, but the direct semaglutide-to-night-sweat pathway has not been tested as a single pathway in humans.
What Does Drug Safety Surveillance Data Show About Sweating
A 2025 retrospective analysis of adverse events across six GLP-1 agonists identified hyperhidrosis as one of the five top cutaneous adverse reactions, reaching statistical significance (P = 0.000). Rates were higher in individuals using GLP-1 agonists for type 2 diabetes compared to weight management, suggesting that the metabolic and autonomic context of insulin-resistant states amplifies the sweating response (Daniel et al., 2025).
How Do the Three Mechanisms Connect Into One Pathway
These mechanisms overlap through GLP-1 receptor signaling, hypothalamic AMPK pathways, sympathetic outflow, BAT heat production, and eccrine sweat gland activation. The strongest evidence supports the individual links; the full semaglutide-to-night-sweat chain remains an evidence-based mechanistic inference.
How Does Weight Loss on Semaglutide Change Your Body Temperature at Night
Sleep onset depends on a drop in core body temperature driven by heat dissipation through the skin. Obesity impairs this process — excess adipose tissue insulates the body, trapping metabolic heat and raising nocturnal core temperature. When semaglutide produces rapid weight loss, two competing forces may emerge: reduced insulating fat may improve heat dissipation over time, while acute metabolic changes — altered energy expenditure, sympathetic activity, and changing body composition — may temporarily change nocturnal temperature regulation (Brown et al., 2017).
Why Does Core Body Temperature Affect Sleep Onset
Sleep onset requires a fall in core body temperature, driven by peripheral vasodilation and heat dissipation through the skin. When nocturnal core body temperature stays high, sleep onset can become more difficult and sleep may become more fragmented (Brown et al., 2017).
In people with obesity, excess adipose tissue acts as insulation. It traps metabolic heat and sustains high nocturnal core body temperature, creating a feedback loop where adiposity impairs sleep through temperature. This is one of the populations where semaglutide is commonly prescribed.
Why Do Night Sweats Peak During Early Semaglutide Use
During early semaglutide use, rapid metabolic changes — altered sympathetic tone, BAT activation signals, and changing energy expenditure — may temporarily affect nocturnal temperature regulation before sustained fat loss improves heat dissipation. This helps explain why night sweats can be more pronounced during the first weeks and during dose escalation, then ease as weight stabilizes.
Lean mass loss adds another variable. Lean mass loss during semaglutide-associated weight loss varies across studies; one systematic review found reductions ranging from almost 0% to 40% of total weight loss (Bikou et al., 2024). Muscle contributes to resting metabolic heat production. As lean mass decreases, the thermogenic profile changes — potentially affecting the amplitude of the nocturnal temperature drop.
How Does This Framework Apply to Semaglutide Users
Brown et al. (2017) proposed that elevated nocturnal core body temperature may help explain the co-occurrence of overweight, sleep disruption, late-night eating, and sedentary behavior. This framework may be relevant to semaglutide users because the drug produces rapid metabolic changes in many people who already have obesity, insulin resistance, or sleep disruption.
Image: DMH Glp1r KD decreases energy expenditure and BAT thermogenesis.
Does Ozempic Affect Autonomic Tone and Sweating
In a randomized, double-blind crossover trial, liraglutide increased heart rate by 8.1 beats per minute and reduced heart rate variability by 33.9 milliseconds compared to placebo. Nighttime heart rate increased by 6.3 beats per minute (P = 0.026). This is evidence that liraglutide can raise heart rate and reduce HRV even during weight loss and metabolic improvement. Eccrine sweat glands are innervated by cholinergic sympathetic fibers — when sympathetic tone rises at night, sweat gland activation follows (Kumarathurai et al., 2017).
What Do Human Trials Show About Semaglutide and Autonomic Tone
A double-blind, placebo-controlled crossover trial in 27 overweight individuals with type 2 diabetes measured the autonomic effects of liraglutide (Kumarathurai et al., 2017):
- Heart rate increased by 8.1 bpm compared to placebo (P = 0.003)
- SDNN (the composite marker of autonomic regulation) decreased by 33.9 ms (P < 0.001)
- High-frequency HRV (a marker of parasympathetic vagal tone) decreased by 0.7 log-ms squared (P = 0.026)
- Nighttime heart rate increased by 6.3 bpm (P = 0.026)
These effects persisted despite weight loss and metabolic improvement, suggesting they were not simply secondary to weight change.
What Does Wearable Device Data Show About Heart Rate on Ozempic
A 2025 study of 66 participants monitored continuously via wearable devices over 12 weeks reproduced the autonomic findings in a naturalistic population. Resting heart rate increased by 3.2 bpm and HRV decreased by 6.2 ms. Causal inference analysis identified HRV reduction as the mediating pathway through which GLP-1 agonists raise resting heart rate. Physical activity partially attenuated the heart rate increase (Grosicki et al., 2025).
Why Does Sympathetic Activation During Sleep Drive Night Sweats
During normal sleep, autonomic tone tends to move toward parasympathetic dominance — heart rate drops, HRV generally increases, and sweating is usually lower unless heat load, arousals, or autonomic activation intervene. GLP-1 receptor agonists may blunt this nighttime transition in some users by raising heart rate and lowering HRV.
Eccrine sweat glands are activated by acetylcholine released from sympathetic fibers. This is the anatomical link that makes GLP-1-related sweating plausible: GLP-1 receptor agonists can affect autonomic tone, and sympathetic fibers innervate sweat glands.
Because semaglutide acts on the same receptor class as liraglutide, similar autonomic effects are plausible, but the magnitude cannot be assumed from liraglutide data alone.
When Do Ozempic Night Sweats Stop
Night sweats reported during GLP-1 use often appear during dose escalation or the first weeks at a new dose, then may ease as the body adapts to the new metabolic state. The likely mechanisms include changing glucose patterns, autonomic adaptation at steady-state drug levels, and thermoregulatory recalibration as sustained weight loss changes heat dissipation.
Why Do Night Sweats Return With Each Dose Increase
Higher semaglutide doses may produce stronger GLP-1 receptor-mediated autonomic and thermogenic effects, although dose-specific night-sweat data are not available. The standard titration schedule (0.25 mg to 0.5 mg to 1.0 mg to 2.4 mg) means users typically experience multiple cycles of intensified sweating followed by partial adaptation as each dose stabilizes. Night sweats may return with dose increases and then ease as the new dose stabilizes, but the two-to-four-week timeline is based on clinical pattern recognition rather than controlled night-sweat trials.
Does Blood Sugar Stabilization Reduce Nocturnal Sweating Over Time
Rapid changes in food intake and postprandial glucose dynamics early in semaglutide use may contribute to adrenergic sweating in some users. As glucose patterns stabilize at each dose, this contributor attenuates. For the full mechanism of nocturnal glucose disruption on semaglutide, see Why Does Ozempic Wake You Up at 3am The Blood Sugar Crash on GLP-1 Drugs.
Does the Body Adapt to Ozempic Autonomic Effects Over Time
Autonomic adaptation at steady-state drug levels is plausible, but the timing and magnitude have not been well quantified for semaglutide-related night sweats. The Kumarathurai et al. (2017) and Grosicki et al. (2025) autonomic data were measured at stable doses, indicating that the sympathetic elevation persists to some degree even after adaptation.
Can Sleep Apnea Improvement Offset Ozempic Night Sweats
GLP-1 agonists reduce obstructive sleep apnea severity. This matters for night sweats because obstructive sleep apnea is associated with frequent nocturnal sweating, and sweating improves in some patients when sleep apnea is treated. A 2025 meta-analysis of 1,067 participants found GLP-1 agonists reduced the apnea-hypopnea index by 9.48 events per hour (Li et al., 2025). In non-diabetic adults with obesity, the reduction was 16.6 events per hour (Kow et al., 2025).
As sleep apnea improves with weight loss, this source of nocturnal autonomic stress decreases — partially offsetting the drug-driven sympathetic activation. Recent review evidence notes that an open question remains: GLP-1 agonists may improve sleep apnea only through weight loss, or they may also have direct respiratory effects (Mifsud et al., 2025).
What Is the Overall Trajectory of Night Sweats on Semaglutide
Night sweats may improve over weeks to months as weight stabilizes and metabolic adaptation occurs. The degree of resolution depends on individual autonomic sensitivity, the magnitude of weight loss, and whether sleep apnea was contributing. Some autonomic elevation may persist during use, based on liraglutide and wearable GLP-1 receptor agonist data.
Night sweats from GLP-1 drugs are one expression of a broader thermoregulatory and autonomic disruption that affects sleep quality. Semaglutide may also affect wakefulness circuitry, glucose dynamics, and circadian timing — each of which could interact with the autonomic effects that contribute to sweating. Sleep disruption from metabolic causes rarely has a single driver.
Find out which causes might be driving your sleep disruption.
Frequently Asked Questions
Are Night Sweats a Common Side Effect of GLP-1 Medications
Hyperhidrosis (excessive sweating) is identified as one of the five most common reported cutaneous adverse reactions across six GLP-1 agonists in FDA pharmacovigilance data, with the indication comparison reported as P = 0.000 (Daniel et al., 2025). Night sweats are reported in user communities, though controlled trials generally do not separate daytime from nighttime sweating in adverse-event tracking.
The pharmacovigilance signal appears class-wide rather than semaglutide-specific. The Daniel et al. (2025) analysis covered exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide, and tirzepatide, with no statistically significant variation among individual drugs. Because trial-reported adverse events group all sweating together — without distinguishing nighttime from daytime — the published literature likely underestimates nocturnal sweating as a separate experience.
Does Ozempic Night Sweating Indicate a Blood Sugar Problem
Sweating is a recognized adrenergic response during hypoglycemia, and semaglutide can alter food intake and postprandial glucose dynamics. However, GLP-1-related sweating may also be autonomic: GLP-1 receptor agonists can raise heart rate and lower HRV, and sweat glands are activated by sympathetic cholinergic fibers. When sweating is accompanied by shaking, confusion, or rapid heartbeat, checking glucose can help distinguish a glycemic episode from a primarily autonomic one (Kumarathurai et al., 2017; Kenny, 2018).
Semaglutide is less likely to cause true hypoglycemia than insulin or sulfonylureas because its insulin secretion is glucose-dependent — meaning it stimulates insulin release proportionally to blood glucose concentration. This makes an autonomic explanation plausible even when glucose is stable. For the full mechanism of nocturnal glucose disruption on semaglutide, see Why Does Ozempic Wake You Up at 3am The Blood Sugar Crash on GLP-1 Drugs.
Can Cooling Your Bedroom Help With Ozempic Night Sweats
Lowering bedroom temperature supports the core body temperature drop required for sleep onset. When semaglutide raises sympathetic tone and BAT thermogenesis, the body produces more metabolic heat. A cooler environment increases the thermal gradient between skin and air, improving heat dissipation and partially offsetting the drug-driven temperature increase (Brown et al., 2017).
A cooler bedroom can support heat loss when body heat production is elevated. Cooling the room addresses the thermal environment rather than the drug’s autonomic or thermogenic effects. The autonomic effect is drug-driven and cannot be fully offset by environmental changes alone, but reducing ambient temperature removes one barrier to the core body temperature drop that sleep onset requires.
Do Ozempic Night Sweats Get Worse at Higher Doses
Higher semaglutide doses may intensify GLP-1 receptor-mediated autonomic and thermogenic effects, both of which could contribute to sweating. The standard titration schedule means users typically experience multiple cycles of intensified sweating followed by partial adaptation as each dose stabilizes. Users commonly report that night sweats return or worsen with dose increases before easing, but controlled studies have not established a precise two-to-four-week sweating timeline.
A dose-response pattern would be consistent with GLP-1 pharmacology, but the semaglutide-specific pathway from dose to hypothalamic AMPK inhibition, sympathetic outflow, BAT activation, and night sweats has not been tested directly in humans. The Kumarathurai et al. (2017) autonomic data — measured at stable doses — demonstrates that the sympathetic elevation partially persists even after adaptation, meaning each dose level carries its own baseline of autonomic activation. For a detailed explanation of the titration-sleep cycle, see Does Your Ozempic Dose Increase Restart Your Insomnia.
Does Mounjaro Cause the Same Night Sweats as Ozempic
Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist. The GLP-1 component can engage overlapping hypothalamic thermoregulatory and autonomic pathways that may contribute to sweating on semaglutide. The FDA pharmacovigilance analysis that identified hyperhidrosis as a class-wide adverse effect covered GLP-1 agonists broadly, with no statistically significant variation among individual drugs (Daniel et al., 2025).
No study has directly compared sweating rates between semaglutide and tirzepatide. The class-wide nature of the hyperhidrosis finding (Daniel et al., 2025) applies to both drugs. Tirzepatide’s GIP receptor component may change the overall metabolic and autonomic profile, but direct sweating comparisons are not available. On the other hand, tirzepatide shows greater sleep apnea improvement — a reduction of 21.86 events per hour in AHI compared to 5.10 for liraglutide (Li et al., 2025) — which could reduce sleep-apnea-related night sweats in people whose sweating is partly driven by obstructive sleep apnea.
Related Reading
- Metabolic Sleep Disruption — The full metabolic sleep framework covering glucose regulation, insulin resistance, mitochondrial decline, NAD+ loss, and fat metabolism
- Does Ozempic Cause Insomnia What GLP-1 Drugs Do to Your Sleep — The broad overview of GLP-1 sleep side effects and mechanisms
- Why Does Ozempic Make You Tired But Keep You Awake — How GLP-1 drugs activate orexin/wakefulness circuitry while appetite suppression can create fatigue
- Why Does Ozempic Wake You Up at 3am — How lower overnight fuel availability and counter-regulatory hormones can contribute to 3am waking
- Does Ozempic Give You Vivid Dreams — How GLP-1 drugs may affect dream intensity through arousal and neuropsychiatric pathways
- Does Eating Too Little on Ozempic Cause Insomnia — How appetite suppression can affect tryptophan, serotonin, melatonin, and overnight glucose stability
- Does Your Ozempic Injection Day Disrupt Your Sleep The 24-48 Hour Pattern — Why sleep disruption can follow a weekly pattern tied to injection timing and peak drug exposure
- Does Your Semaglutide Dose Increase Restart Your Insomnia Why Each Titration Can Disrupt Sleep Again — Why each titration step can restart sleep disruption before adaptation catches up
- Can You Take Melatonin, Magnesium, or Sleep Aids While on Ozempic — How melatonin, magnesium, DORAs, and other sleep aids intersect with GLP-1 physiology
- Does Ozempic Give You Anxiety at Night Why GLP-1 Drugs May Contribute to Nighttime Panic — How orexin activation, HPA-axis signaling, and glucose instability may contribute to nighttime anxiety
- Do GLP-1 Drugs Disrupt Your Body Clock Ozempic, Circadian Rhythms, and Melatonin — How GLP-1 secretion rhythms, food timing, peripheral clocks, and melatonin intersect
- Ozempic Nausea and Sleep: How Stomach Side Effects Keep You Awake at Night — How delayed gastric emptying, reflux, and nausea can fragment sleep
- Will Your Sleep Go Back to Normal When You Stop Ozempic — What is known and not known about sleep after semaglutide discontinuation
- Does Ozempic Muscle Loss Affect Your Sleep Sarcopenia, Temperature, and Deep Sleep — How lean-mass loss, thermoregulation, and deep sleep can interact during GLP-1 weight loss
- Could Ozempic Contribute to Restless Legs at Night Iron, B12, and the Dopamine Connection — How iron, B12, dopamine, and rapid weight loss may intersect with restless legs at night
- Does Compounded Semaglutide Affect Sleep Differently Than Brand-Name Ozempic — How dose variability, formulation differences, and adverse-event tracking can affect sleep side effects
- Ozempic and Sleep After 40: Why GLP-1 Side Effects Can Feel Different as You Age — Why GLP-1 sleep effects can land differently after 40 because of muscle, hormones, and glucose regulation
References
- Arnardottir, E. S., Janson, C., Bjornsdottir, E., Benediktsdottir, B., Juliusson, S., Kuna, S. T., Pack, A. I., Gislason, T., & Bjornsdottir, S. (2013). Nocturnal sweating–a common symptom of obstructive sleep apnoea: the Icelandic sleep apnoea cohort. BMJ Open, 3(5), e002795. https://pubmed.ncbi.nlm.nih.gov/23674447/
- Baggio, L. L., & Drucker, D. J. (2021). Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocrine Reviews, 42(2), 101-132. https://pubmed.ncbi.nlm.nih.gov/33320179/
- Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Ferno, J., Salvador, J., Escalada, J., Dieguez, C., Lopez, M., Fruhbeck, G., & Nogueiras, R. (2014). GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes, 63(10), 3346-3358. https://pubmed.ncbi.nlm.nih.gov/24917578/
- Bikou, O., Angelidi, A. M., Liakos, A., & Koliaki, C. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opinion on Pharmacotherapy, 25(8), 1045-1054. https://pubmed.ncbi.nlm.nih.gov/38629387/
- Brown, R. F., Thorsteinsson, E. B., Smithson, M., Birmingham, C. L., Aljarallah, H., & Nolan, C. (2017). Can body temperature dysregulation explain the co-occurrence between overweight/obesity, sleep impairment, late-night eating, and a sedentary lifestyle Eating and Weight Disorders, 22(4), 599-608. https://pubmed.ncbi.nlm.nih.gov/28929462/
- Daniel, S., Waggett, S., Lyles, E., Sagut, P., Shamaei Zadeh, P., Marcelletti, A., Stegura, C., & Wine Lee, L. (2025). A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies. Journal of Drugs in Dermatology, 24(4), 413-415. https://pubmed.ncbi.nlm.nih.gov/40196945/
- Grosicki, G. J., Kim, J., Fielding, F., Jasinski, S. R., Chapman, C., von Hippel, W., & Holmes, K. E. (2025). Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference. American Journal of Physiology. Heart and Circulatory Physiology, 328(2), H235-H241. https://pubmed.ncbi.nlm.nih.gov/39705534/
- Kenny, G. P. (2018). Sweating as a heat loss thermoeffector. Handbook of Clinical Neurology, 156, 211-232. https://pubmed.ncbi.nlm.nih.gov/30454591/
- Kow, C. S., Ramachandram, D. S., Hasan, S. S., & Thiruchelvam, K. (2025). Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials. Sleep Medicine, 129, 40-44. https://pubmed.ncbi.nlm.nih.gov/39978242/
- Kumarathurai, P., Anholm, C., Larsen, B. S., Olsen, R. H., Madsbad, S., Kristiansen, O., Nielsen, O. W., Haugaard, S. B., & Sajadieh, A. (2017). Effects of liraglutide on heart rate and heart rate variability: A randomized, double-blind, placebo-controlled crossover study. Diabetes Care, 40(1), 117-124. https://pubmed.ncbi.nlm.nih.gov/27797930/
- Lee, S. J., Sanchez-Watts, G., Krieger, J. P., Pignalosa, A., Norell, P. N., Cortella, A., Pettersen, K. G., Vrdoljak, D., Hayes, M. R., Kanoski, S. E., Langhans, W., & Watts, A. G. (2018). Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. Molecular Metabolism, 11, 33-46. https://pubmed.ncbi.nlm.nih.gov/29650350/
- Li, M., Lin, H., Yang, Q., Zhang, X., Zhou, Q., Shi, J., & Ge, F. (2025). Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. Sleep, 48(4), zsae280. https://pubmed.ncbi.nlm.nih.gov/39626095/
- Mifsud, C. S., Kolla, B. P., Rushlow, D. R., & Mansukhani, M. P. (2025). The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea. Expert Opinion on Pharmacotherapy, 26(14-15), 1529-1538. https://pubmed.ncbi.nlm.nih.gov/41114602/
- O’Shea, D., Gunn, I., Chen, X., Bloom, S., & Herbert, J. (1996). A role for central glucagon-like peptide-1 in temperature regulation. Neuroreport, 7(3), 830-832. https://pubmed.ncbi.nlm.nih.gov/8733755/
- Zhyzhneuskaya, S., Kander, T., Borovcanin, M., & Abbara, A. (2025). Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: A narrative review. Neurology and Therapy, 14(4), 1477-1496. https://pubmed.ncbi.nlm.nih.gov/40172827/
Written by Kat Fu, M.S., M.S. – Last reviewed: May 2026 – 15 references cited